Please try another search
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
| Name | Age | Since | Title |
|---|---|---|---|
| Michael M. Morrissey | 61 | 2003 | CEO, President & Director |
| Jack L. Wyszomierski | 66 | 2004 | Independent Director |
| Alan M. Garber | 66 | 2005 | Independent Director |
| Julie Anne Smith | 52 | 2016 | Independent Director |
| Jacqueline Wright | 63 | 2021 | Independent Director |
| Tomas J. Heyman | 67 | 2023 | Independent Director |
| Tomas Heyman | - | 2023 | Director |
| Dave Johnson | - | 2023 | Director |
| Robert Lee Oliver | 64 | 2023 | Independent Director |
| Stelios Papadopoulos | 76 | 1994 | Co-Founder & Chair of the Board |
| Ronald M. Evans | 75 | - | Member of the Scientific Advisory Board |
| Maria C. Freire | 70 | 2018 | Independent Director |
| George H. Poste | 80 | 2004 | Independent Director |
| Charles L. Sawyers | 65 | - | Member of the Scientific Advisory Board |
| Mary C. Beckerle | 69 | 2024 | Independent Director |
| Sue Gail Eckhardt | 66 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
